High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: Efficacy and toxicity

Archives of Internal Medicine

Volumn 166, Issue 19, 2006, Pages 2138-2144

  Hidayat, Levita K ^a,b   Hsu, Donald I ^c   Quist, Ryan ^c   Shriner, Kimberly A ^b   Wong Beringer, Annie ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b HUNTINGTON MEMORIAL HOSPITAL   (United States)

^c WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMPHOTERICIN B; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; LINEZOLID; RIFAMPICIN; VANCOMYCIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NEPHROTOXICITY; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; FEMALE; HUMANS; MALE; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; SAFETY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 33750285524     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.166.19.2138     Document Type: Article

References (22)

1. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32:470-485.
2. Shukla SK. Community-associated methicillin-resistant Staphylococcus aureus and its emerging virulence. Clin Med Res. 2005;3:57-60.
3. Stevens DL. The role of vancomycin in the treatment paradigm. Clin Infect Dis. 2006;42:S51-S57.
4. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004;42:2398-2402.
5. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis. 2004;38:1700-1705.
6. Wootton M, Walsh TR, Macgowan AP. Evidence for reduction in breakpoints used to determine vancomycin susceptibility in Staphylococcus aureus. Antimicrob Agents Chemother. 2005;49:3982-3983.
7. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: 16th Informational Supplement. Wayne, Pa: Clinical and Laboratory Standards Institute; 2006:M100-S16.
8. Larsson AJ, Walker KJ, Raddatz JK, Rotschafer JC. The concentration-independent effect of monoexponential and bioexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions. J Antimicrob Chemother. 1996;38:589-597.
9. Zimmermann AE, Katona BG, Plaisance KI. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. Pharmacotherapy. 1995;15:85-91.
10. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42(suppl 1):S35-S39.
11. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43:925-942.
12. Karam CM, McKinnon PS, Neuhauser MM, Rybak MJ. Outcome assessment of minimizing vancomycin monitoring and dosing adjustments. Pharmacotherapy. 1999;19:257-266.
13. Cruciani M, Gatti G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother. 1996;38:865-869.
14. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388-416.
15. Garner JS, Jarvis WR, Emori TG, et al. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16:128-140.
16. Jones RN. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis. 2006;42:S13-S24.
17. Walsh TR, Bolmstrom A, Qwarnstrom A, et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol. 2001;39:2439-2444.
18. Sancak B, Ercis S, Menemenlioglu D, Colakoglu S, Hascelik G. Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital. J Antimicrob Chemother. 2005;56:519-523.
19. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin intermediate Staphylococcus aureus. Clin Infect Dis. 2004;38:448-451.
20. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2002;34:1481-1490.
21. Rubinstein E, Cammarata S, Oliphant T, Wunderink R; Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind multicenter study. Clin Infect Dis. 2001;32:402-412.
22. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother. 1990;25:679-687.